February 1, 2008Current Opinion in Internal Medicine
Current understanding of heart failure with preserved ejection fraction
Key result
Heart failure with preserved ejection fraction remains poorly understood with limited evidence-based therapies, though renin-angiotensin system blockade may reduce associated morbidity.
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
Design
Review
Authors
Discussion
Loading...
Member takes
Implication
HFpEF care remains largely supportive given limited therapies; leaves open targeted trials addressing core mechanisms.
Structured PICO
P
Population
Patients with heart failure with preserved ejection fraction (HFpEF)
This review highlights the incomplete understanding of HFpEF pathophysiology and the lack of evidence-based therapies to reduce mortality in this population.
Cite This Study
Akshay S. Desai (2008) conducted a review in Heart failure with preserved ejection fraction. Heart failure with preserved ejection fraction remains poorly understood with limited evidence-based therapies, though renin-angiotensin system blockade may reduce associated morbidity.